Tsai, Chia-Kuang
Tsai, Chia-Lin
Lin, Guan-Yu
Yang, Fu-Chi http://orcid.org/0000-0001-6831-3634
Wang, Shuu-Jiun
Funding for this research was provided by:
Ministry of Science and Technology, Taiwan (MOST 108-2314-B-016-023-, MOST 110-2314-B-016 -036 -MY2, MOST109-2321-B-010-006, MOST108-2314-B-010-023-, MOST 110-2314-B-016-035-)
Article History
Accepted: 16 February 2022
First Online: 26 February 2022
Declarations
:
: Chia-Kuang Tsai, Chia-Lin Tsai, Guan-Yu Lin and Fu-Chi Yang declare no conflicts of interest. Shuu-Jiun Wang has served on the advisory boards of Daiichi-Sankyo, Eli Lilly and Novartis; has received honoraria as a moderator from Allergan/AbbVie, Pfizer, Eli Lilly, Biogen and Eisai and has been the PI in trials sponsored by Eli Lilly, Novartis, and Allergan/AbbVie. He has received research grants from the Taiwan Minister of Technology and Science (MOST), Brain Research Center, National Yang-Ming University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan, Taipei Veterans General Hospital, Taiwan Headache Society and Taiwan branches of Eli Lilly, Novartis, and Pfizer.
: This article does not contain any studies with human or animal subjects performed by any of the authors.